Synaptogenix EBIT Margin 2020-2025 | TAOX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Synaptogenix ebit margin from 2020 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Synaptogenix ebit margin from 2020 to 2025. Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$251.1B
Amgen (AMGN)	$158.1B
Gilead Sciences (GILD)	$142.4B
Vertex Pharmaceuticals (VRTX)	$101.3B
Bristol Myers Squibb (BMY)	$97.5B
GSK (GSK)	$81.9B
CSL (CSLLY)	$68.2B
Regeneron Pharmaceuticals (REGN)	$62.5B
Alnylam Pharmaceuticals (ALNY)	$59.6B
Argenex SE (ARGX)	$40.4B
Insmed (INSM)	$27.9B
BioNTech SE (BNTX)	$26.7B
Royalty Pharma (RPRX)	$21.2B
Biogen (BIIB)	$20.4B
Incyte (INCY)	$16.6B
Genmab (GNMSF)	$16.1B
Genmab (GMAB)	$15.8B
Illumina (ILMN)	$15.6B
Ascendis Pharma (ASND)	$11.9B
BioMarin Pharmaceutical (BMRN)	$11.2B
QIAGEN (QGEN)	$11.1B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
Moderna (MRNA)	$10.6B
Exelixis (EXEL)	$10.4B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Exact Sciences (EXAS)	$9B
Bio-Techne Corp (TECH)	$8.9B
Halozyme Therapeutics (HALO)	$8.4B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.1B